- Home
- FC vs MSLE Comparison
FC vs MSLE Comparison
Compare FC & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FC | MSLE |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.8M | 186.9M |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | FC | MSLE |
|---|---|---|
| Price | $18.64 | $6.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $31.00 | $24.17 |
| AVG Volume (30 Days) | 37.4K | ★ 65.9K |
| Earning Date | 11-04-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $267,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $5.44 |
| 52 Week High | $26.81 | $13.39 |
Technical Indicators
Market Signals| Indicator | FC | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 31.86 |
| Support Level | $18.75 | $5.52 |
| Resistance Level | $19.21 | $10.58 |
| Average True Range (ATR) | 0.68 | 0.55 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 79.48 | 10.53 |
Price Performance
Historical ComparisonAbout FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.